Online inquiry

IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4900MR)

This product GTTS-WQ4900MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ACVR2 gene. The antibody can be applied in Cachexia, Type 2 diabetes, Sarcopenia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001278579.2; NM_001106.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 92; 93
UniProt ID P27037; Q13705
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4900MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5543MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ9871MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ10851MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ11493MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ12847MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ10523MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ10488MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ3340MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW